Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Liabilities (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Total Liabilities for 10 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 7.16% to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, down 7.16% year-over-year, with the annual reading at $7.2 million for FY2025, 7.16% down from the prior year.
  • Total Liabilities for Q4 2025 was $7.2 million at Rein Therapeutics, down from $7.5 million in the prior quarter.
  • The five-year high for Total Liabilities was $9.5 million in Q2 2025, with the low at $1.2 million in Q2 2023.
  • Average Total Liabilities over 5 years is $5.6 million, with a median of $4.9 million recorded in 2021.
  • The sharpest move saw Total Liabilities tumbled 76.76% in 2023, then surged 600.0% in 2024.
  • Over 5 years, Total Liabilities stood at $4.6 million in 2021, then dropped by 26.07% to $3.4 million in 2022, then surged by 127.87% to $7.7 million in 2023, then increased by 1.13% to $7.8 million in 2024, then decreased by 7.16% to $7.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $7.2 million, $7.5 million, and $9.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.